Stock Events

Stock Events

Amylyx Pharmaceuticals 

$33.70
109
-$0.05-0.15% 18:06 Today

Statistics

Day High
33.83
Day Low
33.12
52W High
41.14
52W Low
9.15
Volume
30,121
Avg. Volume
-
Mkt Cap
3.75B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Apr 18
$0.42
Jan 18
$0.36
Oct 17
$0.24
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.55
-0.48
-0.41
-0.34
Expected EPS
-0.38308
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-144.74MNet Income

Analyst Ratings

46.40Average Price Target
The highest estimate is 57.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMLX. It's not an investment recommendation.
NVIDIA
19
NVDA
Microsoft
18
MSFT
Amazon
17
AMZN
Apple
16
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen is a biopharmaceutical company that competes with Amylyx in the neurodegenerative diseases market, particularly in treatments for ALS and Alzheimer's disease.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals develops RNA-targeted therapeutics, competing in the same space as Amylyx by targeting neurological disorders including ALS.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapeutics, directly competing with Amylyx in developing treatments for rare neurological diseases.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that has a broad portfolio, including treatments for neurological conditions like ALS, making it a competitor to Amylyx.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes with Amylyx in the neurology space, particularly in developing treatments for spinal muscular atrophy and other neurodegenerative diseases.
PTC
PTC
Mkt Cap17.05B
PTC Therapeutics operates in the field of genetic disorders, including ALS and other neurological conditions, making it a competitor to Amylyx.
Anavex Life Sciences
AVXL
Mkt Cap277.16M
Anavex Life Sciences Corp. focuses on developing therapies for Alzheimer's and other central nervous system diseases, competing with Amylyx in the neurodegenerative space.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical targets rare genetic diseases with some overlap in the neurological space, making it a competitor to Amylyx.
Akebia Therapeutics
AKBA
Mkt Cap243.47M
Akebia Therapeutics, while primarily focused on kidney disease, is exploring treatments in related areas that could compete with Amylyx's neurological disease focus.

About

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Show more...
CEO
Joshua Cohen
Employees
136
Country
United States
ISIN
US03237H1014

Listings

BOATS
BOATS
AMLX.BOATS
XNAS
US
AMLX

0 Comments

Share your thoughts

FAQ

What is Amylyx Pharmaceuticals stock price today?▼
The current price of AMLX is $33.70 USD — it has decreased by -0.15% in the past 24 hours. Watch Amylyx Pharmaceuticals stock price performance more closely on the chart.
What is Amylyx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Amylyx Pharmaceuticals stocks are traded under the ticker AMLX.
Is Amylyx Pharmaceuticals stock price growing?▼
AMLX stock has fallen by -10.34% compared to the previous week, the month change is a +65.36% rise, over the last year Amylyx Pharmaceuticals has showed a +258.05% increase.
What is Amylyx Pharmaceuticals market cap?▼
Today Amylyx Pharmaceuticals has the market capitalization of 3.75B
When is the next Amylyx Pharmaceuticals earnings date?▼
Amylyx Pharmaceuticals is going to release the next earnings report on November 05, 2026.
What were Amylyx Pharmaceuticals earnings last quarter?▼
AMLX earnings for the last quarter are -0.39 USD per share, whereas the estimation was -0.36 USD resulting in a -8.06% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amylyx Pharmaceuticals revenue for the last year?▼
Amylyx Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Amylyx Pharmaceuticals net income for the last year?▼
AMLX net income for the last year is -144.74M USD.
Does Amylyx Pharmaceuticals pay dividends?▼
Yes, AMLX dividends are paid quarterly. The last dividend per share was 0.42 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Amylyx Pharmaceuticals have?▼
As of September 01, 2026, the company has 136 employees.
In which sector is Amylyx Pharmaceuticals located?▼
Amylyx Pharmaceuticals operates in the Health & Wellness sector.
When did Amylyx Pharmaceuticals complete a stock split?▼
Amylyx Pharmaceuticals has not had any recent stock splits.
Where is Amylyx Pharmaceuticals headquartered?▼
Amylyx Pharmaceuticals is headquartered in CAMBRIDGE, United States.